{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:39:17Z","timestamp":1794634757638,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100013885","name":"Kementerian Kesihatan Malaysia","doi-asserted-by":"publisher","award":["91000050"],"award-info":[{"award-number":["91000050"]}],"id":[{"id":"10.13039\/501100013885","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-31737-0","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:49:44Z","timestamp":1768398584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and factors associated with metabolic dysfunction-associated fatty liver disease in a multiethnic Asian country"],"prefix":"10.1038","volume":"16","author":[{"given":"Kim Sui","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halizah","family":"Mat Rifin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Fadhli","family":"Mohd Yusoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wah Kheong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishwen Kanna","family":"Yoga Ratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubash Shander","family":"Ganapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamizatul Akmal","family":"Abd Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masni","family":"Mohamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurain","family":"Mohd Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feisul","family":"Mustapha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor Ani","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"31737_CR1","doi-asserted-by":"publisher","first-page":"155217","DOI":"10.1016\/j.metabol.2022.155217","volume":"133","author":"C Boutari","year":"2022","unstructured":"Boutari, C. & Mantzoros, C. S. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to Rage on. Metab. Clin. Exp. 133, 155217. https:\/\/doi.org\/10.1016\/j.metabol.2022.155217 (2022).","journal-title":"Metab. Clin. Exp."},{"key":"31737_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/hep.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatol. (Baltimore Md). 77, 1335\u20131347. https:\/\/doi.org\/10.1097\/hep.0000000000000004 (2023).","journal-title":"Hepatol. (Baltimore Md)"},{"key":"31737_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"JV Lazarus","year":"2022","unstructured":"Lazarus, J. V. et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat. Reviews Gastroenterol. Hepatol. 19, 60\u201378. https:\/\/doi.org\/10.1038\/s41575-021-00523-4 (2022).","journal-title":"Nat. Reviews Gastroenterol. Hepatol."},{"key":"31737_CR4","doi-asserted-by":"publisher","first-page":"972","DOI":"10.14218\/jcth.2021.00201","volume":"9","author":"H Lin","year":"2021","unstructured":"Lin, H., Zhang, X., Li, G., Wong, G. L. H. & Wong, V. W. S. Epidemiology and clinical outcomes of metabolic (Dysfunction)-associated fatty liver disease. J. Clin. Translational Hepatol. 9, 972\u2013982. https:\/\/doi.org\/10.14218\/jcth.2021.00201 (2021).","journal-title":"J. Clin. Translational Hepatol."},{"key":"31737_CR5","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam, M. et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hep. Intl. 14, 889\u2013919. https:\/\/doi.org\/10.1007\/s12072-020-10094-2 (2020).","journal-title":"Hep. Intl."},{"key":"31737_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40795-020-00348-5","volume":"6","author":"EV Goh","year":"2020","unstructured":"Goh, E. V., Azam-Ali, S., McCullough, F. & Roy Mitra The nutrition transition in Malaysia; key drivers and recommendations for improved health outcomes. BMC Nutr. 6, 32. https:\/\/doi.org\/10.1186\/s40795-020-00348-5 (2020).","journal-title":"BMC Nutr."},{"key":"31737_CR7","unstructured":"Institute for Public Health. National Health and Morbidity Survey (NHMS) 2019: Vol 1: NCDs - Non-communicable Diseases: Risk Factors and other Health Problems. (2020)."},{"key":"31737_CR8","doi-asserted-by":"publisher","unstructured":"Chong, B. et al. Trends and predictions of malnutrition and obesity in 204 countries and territories: an analysis of the Global Burden of Disease Study 2019. eClinicalMedicine 57. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101850 (2023).","DOI":"10.1016\/j.eclinm.2023.101850"},{"key":"31737_CR9","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/jgh.12204","volume":"28","author":"WK Chan","year":"2013","unstructured":"Chan, W. K. et al. Non-alcoholic fatty liver disease in diabetics\u2013prevalence and predictive factors in a multiracial hospital clinic population in Malaysia. J. Gastroenterol. Hepatol. 28, 1375\u20131383. https:\/\/doi.org\/10.1111\/jgh.12204 (2013).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"31737_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12072-013-9510-8","volume":"8","author":"WK Chan","year":"2014","unstructured":"Chan, W. K. et al. Non-alcoholic fatty liver disease in a young multiracial Asian population: a worrying ethnic predilection in Malay and Indian males. Hep. Intl. 8, 121\u2013127. https:\/\/doi.org\/10.1007\/s12072-013-9510-8 (2014).","journal-title":"Hep. Intl."},{"key":"31737_CR11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s12072-012-9359-2","volume":"7","author":"SC Goh","year":"2013","unstructured":"Goh, S. C., Ho, E. L. & Goh, K. L. Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia. Hep. Intl. 7, 548\u2013554. https:\/\/doi.org\/10.1007\/s12072-012-9359-2 (2013).","journal-title":"Hep. Intl."},{"key":"31737_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/sdi.13117","volume":"36","author":"WK Wong","year":"2023","unstructured":"Wong, W. K., Chan, W. K., Ganapathy, S. S. & Lim, S. K. Metabolic dysfunction-associated fatty liver disease (MAFLD) and advanced liver fibrosis among Hemodialysis patients in a multiethnic urban population in Malaysia. Semin. Dial. 36, 107\u2013116. https:\/\/doi.org\/10.1111\/sdi.13117 (2023).","journal-title":"Semin. Dial."},{"key":"31737_CR13","unstructured":"Department of Statistics Malaysia. Current population estimates, Malaysia. (Department of Statistics Malaysia, Putrajaya, 2023)."},{"key":"31737_CR14","doi-asserted-by":"publisher","unstructured":"Wan, K. S. et al. Prevalence of metabolic syndrome and metabolic dysfunction-associated fatty liver disease in Malaysia 2023: study protocol for a community-based nationwide cross-sectional survey. BMJ Open 13, e074432. https:\/\/doi.org\/10.1136\/bmjopen-2023-074432 (2023).","DOI":"10.1136\/bmjopen-2023-074432"},{"key":"31737_CR15","doi-asserted-by":"crossref","unstructured":"Khammas, A. S. A. et al. Prevalence and risk factors of sonographically detected Non alcoholic fatty liver disease in a screening centre in Klang Valley, malaysia: an observational cross-sectional study. Porto Biomed. J. 4 (2019).","DOI":"10.1016\/j.pbj.0000000000000031"},{"key":"31737_CR16","doi-asserted-by":"crossref","unstructured":"Chan, W. K. et al. Malaysian society of gastroenterology and hepatology consensus statement on metabolic dysfunction-associated fatty liver disease. J Gastroenterol. Hepatol (2022).","DOI":"10.1111\/jgh.15787"},{"key":"31737_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni, G. et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 6, 1\u20137 (2006).","journal-title":"BMC Gastroenterol."},{"key":"31737_CR18","unstructured":"Ministry of Health Malaysia. Clinical practice guidelines. Management of type 2 diabetes mellitus. (6th edition). (2020)."},{"key":"31737_CR19","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah, A. G. et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatology: Official Clin. Pract. J. Am. Gastroenterological Association. 7, 1104\u20131112. https:\/\/doi.org\/10.1016\/j.cgh.2009.05.033 (2009).","journal-title":"Clin. Gastroenterol. Hepatology: Official Clin. Pract. J. Am. Gastroenterological Association"},{"key":"31737_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21315\/mjms2024.31.4.1","volume":"31","author":"JM Abdullah","year":"2024","unstructured":"Abdullah, J. M., Ismail, A. & Yusoff, M. S. B. Healthy ageing in Malaysia by 2030: Needs, challenges and future directions. Malaysian J. Med. Sciences: MJMS. 31, 1\u201313. https:\/\/doi.org\/10.21315\/mjms2024.31.4.1 (2024).","journal-title":"Malaysian J. Med. Sciences: MJMS"},{"key":"31737_CR21","unstructured":"Department of Statistics Malaysia. Household Income Survey Report 2022 (Putrajaya Malaysia, 2023)."},{"key":"31737_CR22","unstructured":"World Health Organization. Global Physical Activity Questionnaire (GPAQ) Analysis Guide, https:\/\/www.who.int\/docs\/default-source\/ncds\/ncd-surveillance\/gpaq-analysis-guide.pdf."},{"key":"31737_CR23","unstructured":"World Health Organization, Noncommunicable, D. & Mental Health, C. (World Health Organization, Geneva, (2005)."},{"key":"31737_CR24","unstructured":"Ministry of Health Malaysia. Clinical Practice Guidelines. Management of Hypertension 5th edition (2018)."},{"key":"31737_CR25","unstructured":"Ministry of Health Malaysia. Clinical Practice Guidelines. Management of Dyslipidemia 2023. 6th edition. (2023)."},{"key":"31737_CR26","unstructured":"Ministry of Health Malaysia. Clinical Practice Guidelines. Management of Obesity. 2nd edition (2023)."},{"key":"31737_CR27","doi-asserted-by":"crossref","unstructured":"Chan, K. E. et al. Global prevalence and clinical characteristics of metabolic associated fatty liver Disease. A Meta-Analysis and systematic review of 10,739,607 individuals. The J. Clin. Endocrinol. & Metabolism (2022).","DOI":"10.1210\/clinem\/dgac321"},{"key":"31737_CR28","unstructured":"Lala, V., Zubair, M. & Minter, D. A. In StatPearls [internet] (StatPearls Publishing, 2022)."},{"key":"31737_CR29","unstructured":"International Diabetes Federation. IDF Diabetes Atlas 10th edition. (2021)."},{"key":"31737_CR30","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.3350\/cmh.2022.0350","volume":"29","author":"WK Chan","year":"2023","unstructured":"Chan, W. K. Comparison between obese and non-obese nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 29, S58\u2013s67. https:\/\/doi.org\/10.3350\/cmh.2022.0350 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"31737_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/poh2.63","volume":"2","author":"H Huang","year":"2023","unstructured":"Huang, H., Liu, Z., Xu, M., Chen, Y. & Xu, C. Global burden trends of MAFLD-related liver cancer from 1990 to 2019. Portal Hypertens. Cirrhosis. 2, 157\u2013164. https:\/\/doi.org\/10.1002\/poh2.63 (2023).","journal-title":"Portal Hypertens. Cirrhosis"},{"key":"31737_CR32","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/j.cgh.2021.02.030","volume":"20","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Estimating global prevalence of metabolic Dysfunction-Associated fatty liver disease in overweight or obese adults. Clin. Gastroenterol. Hepatol. 20, e573\u2013e582. https:\/\/doi.org\/10.1016\/j.cgh.2021.02.030 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"31737_CR33","doi-asserted-by":"publisher","unstructured":"Yuan, Q. et al. Prevalence and risk factors of Metabolic-Associated fatty liver disease among 73,566 individuals in Beijing, China. Int. J. Environ. Res. Public Health. 19 https:\/\/doi.org\/10.3390\/ijerph19042096 (2022).","DOI":"10.3390\/ijerph19042096"},{"key":"31737_CR34","unstructured":"Institute for Public Health (IPH). Technical report National Health and Morbidity Survey (NHMS) 2023: Non-Communicable Diseases and Healthcare Demand Malaysia. (2024)."},{"key":"31737_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J. Hepatol. 73, 202\u2013209 (2020).","journal-title":"J. Hepatol."},{"key":"31737_CR36","doi-asserted-by":"publisher","unstructured":"Farrell, A. M. et al. A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 ausdiab study. Sci. Rep. 12 (1956). https:\/\/doi.org\/10.1038\/s41598-022-05168-0 (2022).","DOI":"10.1038\/s41598-022-05168-0"},{"key":"31737_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12986-021-00611-x","volume":"18","author":"J Fan","year":"2021","unstructured":"Fan, J. et al. Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population. Nutr. Metab. 18, 1\u201310 (2021).","journal-title":"Nutr. Metab."},{"key":"31737_CR38","doi-asserted-by":"publisher","unstructured":"Ma, X. et al. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol. 20 https:\/\/doi.org\/10.1186\/s12876-020-1165-z (2020).","DOI":"10.1186\/s12876-020-1165-z"},{"key":"31737_CR39","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","volume":"75","author":"D Kim","year":"2021","unstructured":"Kim, D. et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the united States. J. Hepatol. 75, 1284\u20131291 (2021).","journal-title":"J. Hepatol."},{"key":"31737_CR40","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1111\/jgh.16313","volume":"38","author":"S Shahrani","year":"2023","unstructured":"Shahrani, S. et al. Frequency of significant steatosis and compensated advanced chronic liver disease among adults with chronic liver disease. J. Gastroenterol. Hepatol. 38, 1818\u20131822. https:\/\/doi.org\/10.1111\/jgh.16313 (2023).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"31737_CR41","first-page":"199","volume":"76","author":"SR Karuthan","year":"2021","unstructured":"Karuthan, S. R., Koh, P. S., Chinna, K. & Chan, W. K. Barcelona clinic liver cancer and Hong Kong liver cancer staging systems for prediction of survival among hepatocellular carcinoma patients. Med. J. Malay. 76, 199\u2013204 (2021).","journal-title":"Med. J. Malay."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31737-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31737-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31737-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:49:47Z","timestamp":1768398587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31737-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["31737"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-31737-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Wah-Kheong Chan served as a consultant or advisory board member for Abbott, Roche, AbbVie, Boehringer Ingelheim, and Novo Nordisk; and a speaker for Abbott, Novo Nordisk, Echosens, Viatris and Hisky Medical. Other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1922"}}